DE60215676D1 - Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper - Google Patents

Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper

Info

Publication number
DE60215676D1
DE60215676D1 DE60215676T DE60215676T DE60215676D1 DE 60215676 D1 DE60215676 D1 DE 60215676D1 DE 60215676 T DE60215676 T DE 60215676T DE 60215676 T DE60215676 T DE 60215676T DE 60215676 D1 DE60215676 D1 DE 60215676D1
Authority
DE
Germany
Prior art keywords
igg1
hiv
antibodies
epitope
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60215676T
Other languages
English (en)
Other versions
DE60215676T2 (de
Inventor
Gabriela Stiegler
Renate Kunert
Hermann Katinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Publication of DE60215676D1 publication Critical patent/DE60215676D1/de
Application granted granted Critical
Publication of DE60215676T2 publication Critical patent/DE60215676T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60215676T 2001-09-07 2002-09-09 Gegen ein Peptid, das ein kryptisches Epitop von GP41 aus HIV-1 nachahmt gerichteter Körper Expired - Lifetime DE60215676T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31809101P 2001-09-07 2001-09-07
US318091P 2001-09-07
PCT/EP2002/010070 WO2003022879A2 (en) 2001-09-07 2002-09-09 Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them

Publications (2)

Publication Number Publication Date
DE60215676D1 true DE60215676D1 (de) 2006-12-07
DE60215676T2 DE60215676T2 (de) 2007-08-30

Family

ID=23236607

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60215676T Expired - Lifetime DE60215676T2 (de) 2001-09-07 2002-09-09 Gegen ein Peptid, das ein kryptisches Epitop von GP41 aus HIV-1 nachahmt gerichteter Körper

Country Status (8)

Country Link
US (1) US7595049B2 (de)
EP (1) EP1423417B1 (de)
JP (1) JP4243187B2 (de)
AT (1) ATE343592T1 (de)
AU (1) AU2002340880B2 (de)
DE (1) DE60215676T2 (de)
ES (1) ES2274100T3 (de)
WO (1) WO2003022879A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208587A1 (en) * 2002-09-09 2005-09-22 Rosa Cardoso Peptides that bind to broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex. uses thereof, compositions therefrom
GB0228939D0 (en) * 2002-12-12 2003-01-15 Univ Nottingham Peptide presentations for human immunodeficiency disease vaccines
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
CN1997751B (zh) * 2004-05-28 2012-08-29 艾更斯司股份有限公司 结合于psca蛋白的抗体以及相关分子
US8603736B2 (en) * 2004-06-07 2013-12-10 Monogram Biosciences, Inc. Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
CN101198374B (zh) * 2005-05-02 2012-11-21 健康与医药研究学院 具有抗hiv中和活性的抗体或其片段
EP2139516A4 (de) 2007-04-13 2011-06-29 Univ Duke Verfahren zur induzierung neutralisierender antikörper gegen hiv
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
EP4115900A1 (de) * 2021-07-05 2023-01-11 Diaccurate Neuartige antigene und impfstoffe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
JP4873810B2 (ja) * 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導

Also Published As

Publication number Publication date
AU2002340880B2 (en) 2007-08-23
WO2003022879B1 (en) 2003-12-31
ES2274100T3 (es) 2007-05-16
US20040241641A1 (en) 2004-12-02
WO2003022879A2 (en) 2003-03-20
JP4243187B2 (ja) 2009-03-25
ATE343592T1 (de) 2006-11-15
DE60215676T2 (de) 2007-08-30
WO2003022879A3 (en) 2003-12-04
US7595049B2 (en) 2009-09-29
EP1423417B1 (de) 2006-10-25
EP1423417A2 (de) 2004-06-02
JP2005502708A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
Fung et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
Moore et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies
Zwick et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
RU96102594A (ru) Тандемные синтетические hiv-1 пептиды
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DE60215676D1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
DURDA et al. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide
DE69332911T2 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
Pinter Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
Alsmadi et al. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
Franke et al. Synthetic mimetics of the CD4 binding site of HIV-1 gp120 for the design of immunogens.
Hochleitner et al. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A
Sabatier et al. Use of synthetic peptides for the detection of antibodies against the nef reguating protein in sera of HIV-infected patients
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
Hinz et al. Characterization of a trimeric MPER containing HIV-1 gp41 antigen
AU2005223352B2 (en) Novel Tat complexes, and vaccines comprising them
WO2003059953B1 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
AU2002340880A1 (en) Peptides mimicking a cryptic epitope of GP41 HIV-1 and antibodies directed against them
LAMAN et al. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody
AU2017251715A1 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP0581353A1 (de) Monoklonale Antikörper gegen HIV-1 gp120, Zellinien die sie herstellen und entsprechende Epitope-Strukturen
Steimer et al. HIV-1 neutralization directed to epitopes other than linear V3 determinants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition